aberrant salience 1

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/24

flashcard set

Earn XP

Description and Tags

BPMH

25 Terms

1
New cards

what is psychosis

  • a mental state that is characterised by a combination of symptoms, including unusual experiences, belief, and thoughts, which arise from physical or psychological causes

  • symptoms are seen in people with SCZ or SSDs


2
New cards

SCZ spectrum disorders

according to NICE clinical knowledge summaries

  • approximately 0.5% of people aged 16+ have a SSD diagnosis

  • more common in males than females, ratio of 1.4:1

  • typical age of onset is 20-25 for males, and 25-30 for females


3
New cards

characterisation of psychosis symptoms

positive → experiencing something new, e.g. hallucinations, delusions, and illusions

negative → loss of function, e.g. decreases emotional expression and motivation

cognitive → disorganised thinking

motor → changes in movement, e.g. tics, catatonia (freezing)

4
New cards

DSM-5 diagnosis

  • the presence of symptoms is not ‘all or none’, people vary in severity of symptoms

  • DSM-5 has made available the Clinical Rated Dimensions of Psychosis Symptoms Severity scale

  • there are six major SSDs, diagnosed as primary psychotic disorders if disturbances cannot be explained by other condition, background, or a drug/substance


5
New cards

progression of SSDs

  • genetics and adverse early life experiences may make an individual susceptible to psychosis

  • some features of SSDs may be present at a young age, and it is only later that delusions and hallucinations emerge

  • early symptoms that are present before official diagnosis are prodromal symptoms


6
New cards

enlargement of brain ventricles

  • SCZ patients who have a poor treatment outcome (>50% hospitalisation) had larger lateral ventricles than those with successful treatments

  • may be due to shrinkage in surrounding brain tissue

  • antipsychotic medications may be associated with a decrease in lateral ventricle size


7
New cards

hippocampus

  • may be an inverse relationship between hippocampal size and lateral ventricle size

  • studies have observed significant decreases in hippocampal volume in SSDs, more so for patients with poor treatment outcome

  • however hippocampal neurons are more active in patients than controls

  • this may not be due to number of neurons but type, more excitatory pyramidal glutamatergic neurons than interneurons


8
New cards

hippocampal neuron differences

  • some patients with SCZ display a marked reduction in the density of GABAergic interneurons on the hippocampus

  • when a excitatory neuron is no longer inhibited by another cell it becomes more active (is disinhibited)


9
New cards

impacts of dysregulated hippocampal function

  • vital for formation of new memories, this is disrupted in SSDs

  • SCZ patients have difficulty remembering words presented to them

  • disrupted spatial memory

  • reduced ability to habituate ever-present stimuli


10
New cards

stress

  • when one experiences stressful events, the HPA axis becomes activated, causing an increase in cortisol

    • high levels of which can be damaging to the hippocampus

  • individuals that have had an initial psychotic episode show both increases cortisol levels and decreased hippocampal volume

  • for some people, particularly those with a family history of SSDs, stress could be a trigger for the development of psychotic symptoms


11
New cards

dopamine

  • within the midbrain, distinct small groups of DA cells project to forebrain targets

  • excitatory glutamatergic pyramidal neurons of the hippocampus are thought to be overactive in SSD patients

  • evidence suggests that such excessive excitation of these neurons indirectly results in exaggerated dopamine NT in the brain


12
New cards

dopamine pathway

  • most cell bodies in the NAc, which receive glutamate and DA input, are GABAergic and are called medium spiny neurons (MSNs)

  • MSNs project to another nucleus, the ventral pallidum (VP)

  • many cell bodies in the VP are GABAergic, and these neurons project to the ventral tegmental area (VTA)


13
New cards

dopamine signalling in SSDs

  • an increase in glutamate release in NAc which excited MSNs

  • MSNs release more GABA in VP, inhibiting VP neurons

  • VP is now less likely to inhibit VTA

  • VTA dopamine neurons disinhibited- more likely to be active and release dopamine in NAc

DA in the striatum is elevated in SCZ


14
New cards

chlorpromazine

  • in addition to increased NAc DA, people with SSDs may have increased striatal D2 receptors

  • this drug can alleviate positive symptoms of psychosis, able to antagonise DA D2-type receptors

  • these D2 antagonists are called ‘typical’ or 1st gen antipsychotics


15
New cards

clozapine

  • targets D2-type receptors, but also affects other receptors and NT systems, and may impact different brain regions in unique ways

  • more effective at reducing aspects of psychosis

  • the original ‘atypical’ or 2nd gen antipsychotic. these are believed to alleviate hypofrontality in SSDs, and may decrease positive, negative, and cognitive symptoms of SSDs


16
New cards

side effects of antipsychotics

  • extra pyramidal side effects (Parkinson, akathisia, dystonia, tardive diskinesia)

  • prolactin elevation (amenorrhea, galactorrhoea)

  • dysphoria, anhedonia, depressed mood


17
New cards

DSM-5: stimulant use disorder (SUD)

pattern of amphetamine-type substance, cocaine, or other stimulant use leading to clinically significant impairment or distress. must show 2+ symptoms within 12 months.

18
New cards

prevalence of drug use

  • changes dramatically as a function of a number of factors, including drug type, sex/gender, age, country/region, legal system

  • drug prevalence data approximated via residue concentration in wastewater

  • street drugs almost always contain pollutants

  • drug users may unknowingly take more than one drug


19
New cards

basic bio of addiction

most potentially addictive drugs increase DA transmission

there are however many biophysical influences

20
New cards

normal DA release in brain

  • GABA interneurons are located in the VTA and can release GABA onto DA neurons

  • DA neurons hyperpolarise and activation is blunted

  • DA neurons cannot fire APs

  • DA release onto NAc is minimised


21
New cards

effect of opioids on DA release in brain

  • opioid-producing neurons are also in VTA

  • they release β-endorphine (an endogenous opioid), which binds to μ-opioid receptors on GABA terminals

  • terminal is hyperpolarised

  • GABA release is prevented

  • DA neuron is disinhibited, allowing it to fire APs

  • DA is released in the NAc


22
New cards

sensitisation

repeated exposure enhances ability of the drug to increase DA release in the ventral striatum, including NAc

23
New cards

incentive salience model of motivation

  • with repeated drug or gambling exposure, wanting may become enhanced (sensitised), and process facilitated by exaggerated DA transmission

  • excessive wanting can lead to addictive behaviours, even when pleasure associated with the activity decreases

  • this is magnified by experience with uncertainty, and reward-predictive cues, which are salient and can drive relapse


24
New cards

cues

  • DA provides a link, encoding both learning and uncertainty

  • exposure to cues that predict reward evokes DA transmission

  • when there is a high level of uncertainty, DA neurons increase their activity between the cue presentation and potential event / reward

  • DA levels may fluctuate according to lifetime drug use

  • cues associated with drug use can activate brain pathways responsible for relapse

  • in drug addiction, cues can become inappropriately salient due to altered DA signalling in the brain

    • these salient cues can be distracting and negatively impact behaviour


25
New cards

salience of cues and DA are also relevant to psychosis

  • environment / genetic factors

  • dysregulated firing and / or DA release

  • aberrant sense of novelty and an abnormal assignment of salience to stimuli, and internal representation

    • compounded by a lack of habituation

  • delusions are a cognitive schema that the patient develops to explain aberrant salience experience

  • when this aberrant salience captures behaviour or causes distress, leads to attention

  • antipsychotics block dopamine and dampen the salience of normal events